批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/11/21 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/04/28 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/07/22 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/06/07 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/07/08 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2016/05/09 |
SUPPL-9(补充) |
Approval |
Labeling |
901 ORDER
|
|
|
2014/03/04 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/10/31 |
SUPPL-6(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2013/08/28 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/08/13 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/01/18 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2011/04/23 |
ORIG-1(原始申请) |
Approval |
Type 4 - New Combination |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:FAMOTIDINE; IBUPROFEN 剂型/给药途径:TABLET;ORAL 规格:26.6MG;800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022519 |
001 |
NDA |
DUEXIS |
FAMOTIDINE; IBUPROFEN |
TABLET;ORAL |
26.6MG;800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
Discontinued |
Yes |
No |
AB |
2011/04/23
|
HORIZON |